Producers of biopharmaceuticals are challenged to become more efficient in discovering and developing candidate drugs while assuring quality and increasing manufacturing productivity and reducing costs. Advanced instrumental techniques and analytical workflows can help to accelerate the development pipeline and optimize production processes. Thermo Fisher Scientific™ has innovative solutions to support every stage of the bio/pharmaceutical process, from discovery through to production and QC. Our deep understanding of the challenges faced by scientists developing lifesaving medicines allows us to forge partnerships that more quickly deliver next-generation drugs to market.
For more information please visit thermofisher.com/biopharma,
or Connect with us through the Chat here, or Speak to a Specialist
A very exciting Webinar not to miss on SARS-CoV-2!
By attending you can learn how mass spectrometry has been used to identify more than 500 unique sequences from SARS-CoV-2 spike glycoprotein extracellular domain in a complex with human leukocyte antigen class II molecules on antigen presenting cells from a panel of healthy donors. This work by researchers at Eli Lilly and Co. represents the most precise and comprehensive HLA-II immunopeptidomic investigation with SARS-CoV-2 spike glycoprotein and allows for detailed analysis of features, which may aid crucial vaccine development.
Key Learning Objectives:
Achieve deeper characterization insights to secure your biopharmaceutical development
The Thermo Scientific™ HR Multi-Attribute Method (MAM) is a powerful high resolution accurate mass (HRAM)-based workflow that enables comprehensive characterization and monitoring of quality attributes from research to quality control (QC). The HR MAM consists of industry-leading hardware and compliance-ready software as well as a system suitability test specifically developed for the workflow. Built within a safe, compliant environment, the HR MAM enables characterization of biologics with ease and allows potential critical quality attributes (CQAs) to be monitored throughout every stage of the drug development process, while also providing purity testing with the feature of new peak detection (NPD).
Access our brand new MAM Toolkit to learn more about the biopharmaceutical Multi-Attribute Method.
What you are guaranteed to get by accessing it :
Resources for next generation Gene therapy analytics - and more!
From our very popular Leaders in Characterization Webinar series you can still access great information, like the one on how to develop analytics for next generation Gene Therapies! Register to all on-demand content from our Webinar Series dedicated to Leaders in Biopharma Characterization and Control.
